Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease

2014178 citationsJournal Articlegreen Open Access

Authors

Kenneth N. Olivier · Office of Infectious Diseases

Pamela A. Shaw · National Institute of Allergy and Infectious Diseases

Tanya Glaser

Darshana Bhattacharyya

Monika Fleshner

Carmen C. Brewer · National Institute on Deafness and Other Communication Disorders

Christopher Zalewski · National Institute on Deafness and Other Communication Disorders

Les Folio

Abstract

In some patients with treatment-refractory pulmonary nontuberculous mycobacterial disease, the addition of inhaled amikacin was associated with microbiologic and/or symptomatic improvement; however, toxicity was common. Prospective evaluation of inhaled amikacin for mycobacterial disease is warranted.

Topics & Keywords

Mycobacterium research and diagnosis Tuberculosis Research and Epidemiology Infectious Diseases and Mycology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of the American Thoracic Society

Volume 11, Issue 1, pp. 30-35

DOI: 10.1513/annalsats.201307-231oc

Field-Weighted Citation Impact: 14.70